Table 5.

Treatment of 410 enrolled patients in relation to pathologic features during follow-up, compared to the original Oxford study

Pathologic LesionPresent StudyOxford Study
% RAS BlockadeP% Immunosuppressive TherapyP% RAS BlockadeP% Immunosuppressive TherapyP
Mesangial hypercellularity score
    ≤0.582337121
    >0.5890.0850<0.0175>0.0130>0.01
Segmental glomerulosclerosis
    absent81465428
    present880.04420.3181<0.0129>0.01
Endocapillary hypercellularitya
    absent85407617
    present870.31450.5272>0.0145<0.01
Endocapillary hypercellularity
    ≤25% present8641
    >25% present880.5952<0.01
Extracapillary hypercellularityb
absent85377220
present880.42470.0478>0.01390.02
Extracapillary glomerular activity index
    <4870.9136<0.01
Extracapillary glomerular activity index
    ≥48674
Tubular atrophy/interstitial fibrosis
    1 to 25%870.12390.05760.0328>0.01
    26 to 50%88618424
    >50%81508550
  • RAS, renin angiotensin system.

  • a Endocapillary hypercellularity involving no more than or more than 25% glomeruli defined as endocapillary hypercellularity ≤25% or >25%.

  • b Extracapillary glomerular activity index was defined to evaluate the severity of crescent, which was scored by a double weight of >50% circumferential cellular or fibrocellular crescent.